Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Celldex Therapeutics (CLDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 61,454
  • Shares Outstanding, K 12,440
  • Annual Sales, $ 9,540 K
  • Annual Income, $ -151,180 K
  • 60-Month Beta 4.33
  • Price/Sales 6.70
  • Price/Cash Flow 2.62
  • Price/Book 0.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -1.14
  • Number of Estimates 1
  • High Estimate -1.14
  • Low Estimate -1.14
  • Prior Year -2.85
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.38 +12.79%
on 03/08/19
6.22 -20.51%
on 02/25/19
-0.98 (-16.55%)
since 02/22/19
3-Month
2.74 +79.96%
on 12/26/18
11.63 -57.51%
on 02/04/19
+1.94 (+64.67%)
since 12/21/18
52-Week
2.74 +79.96%
on 12/26/18
37.20 -86.72%
on 03/27/18
-31.66 (-86.50%)
since 03/22/18

Most Recent Stories

More News
Celldex Therapeu Shares Down 18.4% Since SmarTrend's Sell Call (CLDX)

SmarTrend identified a Downtrend for Celldex Therapeu (NASDAQ:CLDX) on February 8th, 2019 at $6.38. In approximately 1 month, Celldex Therapeu has returned 18.43% as of today's recent price of $5.20.

CLDX : 4.94 (-3.89%)
Is Celldex Therapeutics (CLDX) Stock Outpacing Its Medical Peers This Year?

Is (CLDX) Outperforming Other Medical Stocks This Year?

CLDX : 4.94 (-3.89%)
16.9% Return Seen to Date on SmarTrend Celldex Therapeu Call (CLDX)

SmarTrend identified a Downtrend for Celldex Therapeu (NASDAQ:CLDX) on February 8th, 2019 at $6.38. In approximately 4 weeks, Celldex Therapeu has returned 16.86% as of today's recent price of $5.30.

CLDX : 4.94 (-3.89%)
Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat

Celldex (CLDX) reports narrower-than-expected loss, while sales miss estimates in the fourth quarter of 2018.

CELG : 88.15 (-1.65%)
CLDX : 4.94 (-3.89%)
LLY : 128.30 (-0.01%)
BMY : 48.16 (-1.55%)
Celldex Provides Corporate Update and Reports Full Year 2018 Results

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2018. The Company will host a conference call at 4:30 p.m. ET...

CLDX : 4.94 (-3.89%)
Celldex to Report Full Year 2018 Business/Financial Results and Host Corporate Update Call

Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release fourth quarter and year-end 2018 financial results on Thursday, March 7, 2019 after the U.S. financial markets close. Celldex executives will host...

CLDX : 4.94 (-3.89%)
Celldex Therapeutics (CLDX) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Celldex Therapeutics (CLDX) closed at $5.92, marking a -1.17% move from the previous day.

CLDX : 4.94 (-3.89%)
Analysis: Positioning to Benefit within Applied Materials, MRC Global, Meritor, Celldex Therapeutics, Quaker Chemical, and Cubic -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Applied Materials, Inc. (NASDAQ:AMAT),...

AMAT : 39.86 (-3.56%)
CUB : 54.55 (-5.56%)
CLDX : 4.94 (-3.89%)
KWR : 196.58 (-4.40%)
MTOR : 20.01 (-5.70%)
MRC : 16.85 (-4.53%)
The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna

The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna

CLDX : 4.94 (-3.89%)
CYTK : 8.75 (-1.02%)
AEZS : 4.14 (-3.04%)
BDSI : 5.11 (-3.58%)
ADRO : 3.67 (-5.17%)
5 Tiny Biotech Stocks With Superb Growth Potential

A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.

CLDX : 4.94 (-3.89%)
CYTK : 8.75 (-1.02%)
CELG : 88.15 (-1.65%)
AEZS : 4.14 (-3.04%)
BDSI : 5.11 (-3.58%)
LLY : 128.30 (-0.01%)
LOXO : 234.80 (+0.06%)
ADRO : 3.67 (-5.17%)
BMY : 48.16 (-1.55%)
TAK : 20.94 (-2.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade CLDX with:

Business Summary

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal...

See More

Key Turning Points

2nd Resistance Point 5.38
1st Resistance Point 5.16
Last Price 4.94
1st Support Level 4.79
2nd Support Level 4.63

See More

52-Week High 37.20
Fibonacci 61.8% 24.04
Fibonacci 50% 19.97
Fibonacci 38.2% 15.91
Last Price 4.94
52-Week Low 2.74

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar